Paper
0
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
Authors
Susan Prockop,Ekaterina Doubrovina
Stephanie Suser,Glenn Heller,Juliet Barker,Parastoo Dahi,Miguel-Ángel Perales,Esperanza Papadopoulos,Craig Sauter,Hugo Castro‐Malaspina,Farid Boulad,Kevin Curran,Sergio Giralt,Boglarka Gyurkocza,Katharine Hsu,Ann Jakubowski,Alan Hanash,Nancy Kernan,Rachel Kobos,Guenther Koehne,Heather Landau,Doris Ponce,Barbara Spitzer,James Young,Gerald Behr,Mark Dunphy,Sofia Haque,Julie Teruya‐Feldstein,Maria Arcila,Christine Moung,Susan Hsu,Aisha Hasan,Richard O’Reilly,Jonathan Barker
+32 authors
,Miguel‐Angel PeralesPublished
Nov 5, 2019
Show more
Save
Tip0
TipSave
Abstract
BACKGROUND. Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.